chr8:51306070–51306693 |
SNTG1
|
Mediates dystrophin binding. Associated with idiopathic scoliosis [49]. |
3 |
2.49E− 09 |
0.0904 |
0.2066 |
0.1012 |
chr3:150265617–150265620 |
SERP1
|
Protein folding and metabolism. Inhibition can downregulate the Wnt/β-catenin pathway in keratinocytes [70]. |
2 |
4.96E− 06 |
0.1754 |
0.0351 |
0.0327 |
chr3:44636619–44636844 |
ZNF197
|
Transcription factor with potential role in skeletal muscle energy metabolism following exercise [71]. |
2 |
0.0008 |
0.3556 |
0.0465 |
0.0267 |
chr22:49875144–49875295 |
C22orf34
|
Chromosome 22 Open Reading Frame 34, uncharacterized protein. |
2 |
0.0040 |
0.3980 |
− 0.0775 |
− 0.0575 |
chr16:1477870–1478718 |
C16orf91
|
Chromosome 16 Open Reading Frame 91, uncharacterized protein. |
3 |
0.0001 |
0.4290 |
− 0.0667 |
− 0.0434 |
chr19:7813422–7813963 |
EXOSC3P2
|
Pseudogene, unknown function. |
3 |
3.81E− 06 |
0.4426 |
− 0.0800 |
− 0.0468 |
chr13:101173617–101174420 |
PCCA
|
Subunit of mitochondrial enzyme critical to energy metabolism [72]. |
8 |
4.01E− 11 |
0.4572 |
− 0.0929 |
− 0.0537 |
chr11:1903176–1903333 |
LSP1
|
Expressed in immune system cells and may regulate motility and transendothelial migration. Potential marker of hepatocellular carcinoma risk [73]. |
2 |
0.0047 |
0.4611 |
− 0.0586 |
− 0.0486 |
chr4:185369135–185370076 |
IRF2
|
Competitively inhibits the IRF1-mediated transcriptional activation of interferons alpha and beta. Decreased expression associated with angiogenesis and inflammation [43, 44]. |
3 |
0.0030 |
0.4752 |
− 0.1271 |
− 0.0100 |
chr4:175241684–175241753 |
CEP44
|
Centrosomal protein |
2 |
0.0071 |
0.4980 |
− 0.1368 |
− 0.0847 |
chr17:72915897–72916509 |
USH1G
|
Auditory and visual function development [50]. |
3 |
0.0009 |
0.5005 |
− 0.0636 |
− 0.0595 |